ArticleCritical care (London, England)2021

Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.

Emma J Kooistra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.